Thrombostatin inhibits induced canine coronary thrombosis

Thrombostatin (RPPGF), an angiotensin converting enzyme metabolite of bradykinin, is an inhibitor of a-thrombin’s ability to activate platelets. We examined the in vivo pharmacokinetics and pharmacodynamics of thrombostatin in rabbits and its ability to inhibit coronary thrombosis induced by electrolytic injury in dogs. Plasma halflife of thrombostatin had a t1 /2 a of 2.6 min and a t1 /2 b of 24 min in rabbits. Ligating the renal arteries did not prolong clearance (t1 /2 a = 2.4 min; t1 /2 b = 12 min). Thrombostatin produced a prolonged in vivo antiplatelet effect. At 30 min after a single intravenous administration in rabbits, thrombostatin’s plasma concentration was